Videos

Lipid testing rates are very low among those under 40 years old. Where do clinicians best target high-risk patients—and how?

Adults 40 years and younger generally aren't tested for lipid level risk—a byproduct of national guidance and clinical trial needs.

Dr. Mulshine and Dr. Rizzo discuss the diagnostic evolution detailed in several studies in the previous decades, and how CT screening can be used to detect lung cancer early in patients.

Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.

Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.

Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.

There currently is not an approved treatment for EoE by the US Food and Drug Administration.

Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

ACG represents the first major in-person conference since the COVID-19 pandemic.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

Dr. Glanzman presented during AAP 2021 about executive function impairments in patients with ADHD.

Students with ADHD have struggled with virtual schooling during the COVID-19 pandemic.

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Executive function can include working memory, behavioral inhibition, and cognitive flexibility.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.